Mitochondria, Cognitive Impairment, and Alzheimer's Disease

To date, the beta amyloid (Aβ) cascade hypothesis remains the main pathogenetic model of Alzheimer's disease (AD), but its role in the majority of sporadic AD cases is unclear. The “mitochondrial cascade hypothesis” could explain many of the biochemical, genetic, and pathological features of sporadic AD. Somatic mutations in mitochondrial DNA (mtDNA) could cause energy failure, increased oxidative stress, and accumulation of Aβ, which in a vicious cycle reinforce the mtDNA damage and the oxidative stress. Despite the evidence of mitochondrial dysfunction in AD, no causative mutations in the mtDNA have been detected so far. Indeed, results of studies on the role of mtDNA haplogroups in AD are controversial. In this review we discuss the role of the mitochondria, and especially of the mtDNA, in the cascade of events leading to neurodegeneration, dementia, and AD

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

The current study was conducted to asses the safety profile and clinical activity of rituximab in combination with fludarabine and cyclophosphamide in patients with recurrent follicular lymphoma (FL). METHODS: This study was a noncomparative, multicenter, phase II study. Between March 2000 and December 2002, 54 patients with recurrent FL were enrolled in the FC+R trial. Patients received fludarabine at a dose of 25 mg/m(2) and cyclophosphamide at a dose of 300 mg/m(2) daily for 3 consecutive days, every 3 weeks for 4 cycles. Rituximab was administered at a dose of 375 mg/m(2) beginning 2 weeks after the first course of fludarabine and cyclophosphamide and then on Day 1 of each cycle thereafter. The planned treatment duration was 10 weeks. RESULTS: Overall, 92% of patients completed the planned therapy in 10 to 14 weeks and 74% achieved a complete response (CR). Among patients with BCL2-positive bone marrow, 86% obtained a molecular disease remission (MR). The median survival from treatment (SFT), the duration of disease remission (DR), and time to disease progression (TTP) had not been reached after a median follow-up of 45 months. Of the baseline characteristics, >2 previous treatments, BCL2-positive bone marrow, and low Follicular Lymphoma International Prognostic Index (FLIPI) score were found to be associated with better DR and/or TTP. Hematologic toxicity was transient and reversible, with the exception of 3 patients with severe and prolonged neutropenia. Three patients presented with infections, 1 of whom died of bronchopneumonia. CONCLUSIONS: The FC+R scheme, a nonanthracycline-containing regimen lasting up to 10 weeks, was found to be relatively well-tolerated and demonstrated significant antilymphoma activity with excellent clinical CR and molecular response rates

Hamiltonian purification

The problem of Hamiltonian purification introduced by Burgarth et al. [D. K. Burgarth et al., Nat. Commun. 5, 5173 (2014)] is formalized and discussed. Specifically, given a set of non-commuting Hamiltonians {h1, . . ., hm} operating on a d-dimensional quantum system Hd, the problem consists in identifying a set of commuting Hamiltonians {H1,...,Hm} operating on a larger dE-dimensional system H_{dE} which embeds H_d as a proper subspace, such that hj = PHjP with P being the projection which allows one to recover Hd from HdE . The notions of spanning-set purification and generator purification of an algebra are also introduced and optimal solutions for u(d) are provided.Comment: 13 pages, 3 figure

Quantum-secured time transfer between precise timing facilities: a field trial with simulated satellite links

Global Navigation Satellite Systems (GNSSs), such as GPS and Galileo, provide precise time and space coordinates globally and constitute part of the critical infrastructure of modern society. To reliably operate GNSS, a highly accurate and stable system time is required, such as the one provided by several independent clocks hosted in Precise Timing Facilities (PTFs) around the world. The relative clock offset between PTFs is periodically measured to have a fallback system to synchronize the GNSS satellite clocks. The security and integrity of the communication between PTFs is of paramount importance: if compromised, it could lead to disruptions to the GNSS service. Therefore, securing the communication between PTFs is a compelling use-case for protection via Quantum Key Distribution (QKD), since this technology provides information-theoretic security. We have performed a field trial demonstration of such a use-case by sharing encrypted time synchronization information between two PTFs, one located in Oberpfaffenhofen (Germany) and one in Matera (Italy)—more than 900 km apart. To bridge this large distance, a satellite-QKD system is required, plus a “last-mile” terrestrial link to connect the optical ground station (OGS) to the actual location of the PTF. In our demonstration, we have deployed two full QKD systems to protect the last-mile connection at both locations and have shown via simulation that upcoming QKD satellites will be able to distribute keys between Oberpfaffenhofen and Matera, exploiting already existing OGSs

Real life use of bendamustine in elderly patients with lymphoid neoplasia

Background. Bendamustine is a cytotoxic alkylating drug with a broad range of indications as a single agent or in combination therapy in lymphoid neoplasia patients. However, its tolerability in elderly patients is still debated. Methods: An observational, retrospective study was carried out; patients with chronic lymphocytic leukemia (CLL) or lymphoma, aged ≥ 65 years old, treated with bendamustine-based regimens in first or subsequent lines between 2010 and 2020 were considered eligible. Results: Overall, 179 patients aged ≥ 65 years were enrolled, 53% between 71 and 79 years old. Cumulative Illness Rating Scale (CIRS) comorbidity score was ≥6 in 54% patients. Overall survival (OS) at 12 months was 95% (95% confidence interval [CI]: 90–97%); after a median follow up of 50 months, median OS was 84 months. The overall response rate was 87%, with 56% complete responses; the median time to progression (TTP) was 61 months. The baseline factors affecting OS by multivariable analysis were sex, histological diagnosis, renal function, and planned bendamustine dose, while only type of lymphoma and bendamustine dose impacted on TTP. Main adverse events were neutropenia (grade ≥ 3: 43%) and infections (any grade: 36%), with 17% of patients requiring hospital admission. Conclusions: The responses to bendamustine, as well as survival, are relevant even in advanced age patients, with a manageable incidence of acute toxicity

International time transfer between precise timing facilities secured with a quantum key distribution network

Global Navigation Satellite Systems (GNSSs), such as GPS and Galileo, provide precise time and space coordinates globally and constitute part of the critical infrastructure of modern society. To reliably operate GNSS, a highly accurate and stable system time is required, such as the one provided by several independent clocks hosted in Precise Timing Facilities (PTFs) around the world. Periodically, the relative clock offset between PTFs is measured to have a fallback system to synchronize the GNSS satellite clocks. The security and integrity of the communication between PTFs is of paramount importance: if compromised, it could lead to disruptions to the GNSS service. Therefore, it is a compelling use-case for protection via Quantum Key Distribution (QKD), since this technology provides information-theoretic security. We have performed a field trial demonstration of such use-case by sharing encrypted time synchronization information between two PTFs, one located in Oberpfaffenhofen (Germany) and one in Matera (Italy) - more than 900km apart as the crow flies. To bridge this large distance, a satellite-QKD system is required, plus a "last-mile" terrestrial link to connect the optical ground station (OGS) to the actual location of the PTF. In our demonstration we have deployed two full QKD systems to protect the last-mile connection at both the locations and have shown via simulation that upcoming QKD satellites will be able to distribute keys between Oberpfaffenhofen and Matera exploiting already existing OGSs

Splenic marginal zone lymphoma: a prognostic model for clinical use.

The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100 000/μL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influence on CSS in multivariate analysis were hemoglobin level less than 12 g/dL, LDH level greater than normal, and albumin level less than 3.5 g/dL. Using these 3 variables, we grouped patients into 3 prognostic categories: low-risk group (41%) with no adverse factors, intermediate-risk group (34%) with one adverse factor, and high-risk group (25%) with 2 or 3 adverse factors. The 5-year CSS rate was 88% for the low-risk group, 73% for the intermediate-risk group, and 50% for the high-risk group. The cause-specific mortality rate (x 1000 person-years) was 20 for the low-risk group, 47 for the intermediate-risk group, and 174 for the high-risk group. This latter group accounted for 54% of all lymphoma-related deaths. In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient. © 2006 by The American Society of Hematology